Business brief
Israeli Defense Megadeals, Consumer Exits, and Biotech Momentum
State defense contractors seal record exports, while Israeli founders score consumer exits and clinical pipeline gains.
Business
Israel's historic defense deal with Greece cements state arms contractors as indispensable air defense suppliers across NATO — shielding trade ties from political disputes.
BackgroundIsrael's state-owned contractors produce world-leading missile interceptors including David's Sling, SPYDER, and Barak MX. European militaries have rapidly expanded defense procurement from Israeli vendors to reinforce regional air security.
- Rafael and Israel Aerospace Industries will manufacture 75% of the hardware in Israel, while subcontracting 25% to Greek firms to fulfill local industrial offset requirements.
- The multi-layered shield provides full-spectrum protection against ballistic missiles, air threats, and autonomous drone swarms across Mediterranean airspace.
- Foreign diplomats highlighted the contract as proof that NATO allies remain heavily reliant on battle-tested Israeli air defense technology despite broader diplomatic friction.
Business
Barilla's buyout of Gal Gadot's Goodles proves celebrity-led consumer brands can capture massive market share from legacy food giants — establishing a blueprint for high-margin exits.
BackgroundGoodles launched in 2021 as a nutrient-dense alternative in the packaged food sector, reaching $70M in annual sales. Israeli celebrity partners served as core founding drivers to position the brand against legacy shelf leaders.
- Goodles achieved profitability in 2024 after raising a Series A round that previously valued the business at $88M, establishing a rare path to profit for venture-backed consumer brands.
- Barilla acquired the business from majority owner L Catterton and celebrity investors, retaining independent brand operations in Santa Cruz to preserve its growth culture.
- The acquisition marks one of the highest-profile consumer exits involving Israeli founders in recent years, proving celebrity-driven packaged goods can attract legacy multinational buyers.
Business
Teva's clinical success in celiac therapy validates its transition toward high-margin specialty biotechs — rebuilding investor confidence in dual-listed Tel Aviv shares.
BackgroundTeva is building a novel therapeutic pipeline alongside its legacy generic drug business. Celiac disease affects millions globally, but no approved medical therapy exists to prevent intestinal damage caused by accidental gluten exposure.
- The Phase 2a study met its primary endpoint, demonstrating statistically significant protection against gluten-induced mucosal damage compared with placebo.
- UBS reaffirmed a Buy rating on Teva shares and raised its price target to $48 following the successful trial readout.
- Positive clinical data strengthens Teva's pivot toward high-margin specialty pharmaceuticals as cash flows from generic drugs are redirected into proprietary biotech development.
Business
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
